An imbalance between excitatory and inhibitory neurotransmitters in amyotrophic lateral sclerosis revealed by use of 3-T proton magnetic resonance spectroscopy.

IMPORTANCE A lack of neuroinhibitory function may result in unopposed excitotoxic neuronal damage in amyotrophic lateral sclerosis (ALS). OBJECTIVE To determine whether there are reductions in γ-aminobutyric acid (GABA) levels and elevations in glutamate-glutamine (Glx) levels in selected brain regions of patients with ALS by use of proton magnetic resonance spectroscopy. DESIGN Case-control study using short echo time and GABA-edited proton magnetic resonance spectroscopy at 3 T with regions of interest in the left motor cortex, left subcortical white matter, and pons; data analyzed using logistic regression, t tests, and Pearson correlations; and post hoc analyses performed to investigate differences between riluzole-naive and riluzole-treated patients with ALS. SETTING Tertiary referral center. PARTICIPANTS Twenty-nine patients with ALS and 30 age- and sex-matched healthy controls. EXPOSURE Fifteen patients were taking 50 mg of riluzole twice a day as part of their routine clinical care for ALS. MAIN OUTCOMES AND MEASURES Levels of GABA, Glx, choline (a marker of cell membrane turnover), creatine (a marker of energy metabolism), myo-inositol (a marker of glial cells), and N-acetylaspartate (a marker of neuronal integrity). RESULTS Patients with ALS had significantly lower levels of GABA in the motor cortex than did healthy controls (P < .01). Patients with ALS also had significantly lower levels of N-acetylaspartate in the motor cortex (P < .01), subcortical white matter (P < .05), and pons (P < .01) and higher levels of myo-inositol in the motor cortex (P < .001) and subcortical white matter (P < .01) than did healthy controls. Riluzole-naive patients with ALS had higher levels of Glx than did riluzole-treated patients with ALS (P < .05 for pons and motor cortex) and healthy controls (P < .05 for pons and motor cortex). Riluzole-naive patients with ALS had higher levels of creatine in the motor cortex (P < .001 for both comparisons) and subcortical white matter (P ≤ .05 for both comparisons) than did riluzole-treated patients with ALS and healthy controls. Riluzole-naive patients with ALS had higher levels of N-acetylaspartate in the motor cortex than did riluzole-treated patients with ALS (P < .01). CONCLUSIONS AND RELEVANCE There are reduced levels of GABA in the motor cortex of patients with ALS. There are elevated levels of Glx in riluzole-naive patients with ALS compared with riluzole-treated patients with ALS and healthy controls. These results point to an imbalance between excitatory and inhibitory neurotransmitters as being important in the pathogenesis of ALS and an antiglutamatergic basis for the effects of riluzole, although additional research efforts are needed.

[1]  E. Kunesch,et al.  Effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis , 2001, Annals of neurology.

[2]  Laura E. Danielian,et al.  White matter alterations differ in primary lateral sclerosis and amyotrophic lateral sclerosis. , 2011, Brain : a journal of neurology.

[3]  C. Zona,et al.  Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole , 2004, Journal of neuroscience research.

[4]  M A Horsfield,et al.  Diffusion tensor MRI assesses corticospinal tract damage in ALS , 1999, Neurology.

[5]  W. Fischer,et al.  Riluzole suppresses motor cortex facilitation in correlation to its plasma level , 2000, Experimental Brain Research.

[6]  Measuring pseudobulbar affect in ALS , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[7]  C. Hanstock,et al.  Detection of cerebral degeneration in amyotrophic lateral sclerosis using high-field magnetic resonance spectroscopy. , 2006, Archives of neurology.

[8]  Matthew C Kiernan,et al.  Biomarkers in amyotrophic lateral sclerosis , 2009, The Lancet Neurology.

[9]  J. Rothstein,et al.  Current hypotheses for the underlying biology of amyotrophic lateral sclerosis , 2009, Annals of neurology.

[10]  S. Petri,et al.  Hyperexcitability and amyotrophic lateral sclerosis , 2012, Neurology.

[11]  H. Mitsumoto,et al.  Amyotrophic lateral sclerosis: Objective upper motor neuron markers , 2002, Current neurology and neuroscience reports.

[12]  A. Nistri,et al.  Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro , 2008, The European journal of neuroscience.

[13]  P. Matthews,et al.  Polarity-Sensitive Modulation of Cortical Neurotransmitters by Transcranial Stimulation , 2009, The Journal of Neuroscience.

[14]  Michel Modo,et al.  Advances in the application of MRI to amyotrophic lateral sclerosis. , 2010, Expert opinion on medical diagnostics.

[15]  Douglas L. Arnold,et al.  Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging , 2006, Journal of Neurology.

[16]  Alessandra Cifra,et al.  Riluzole: what it does to spinal and brainstem neurons and how it does it. , 2013, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[17]  Richard W. Bohannon,et al.  Interrater reliability of a modified Ashworth scale of muscle spasticity. , 1987, Physical therapy.

[18]  R. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[19]  P. Leigh,et al.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.

[20]  M. Filippi,et al.  The Present and the Future of Neuroimaging in Amyotrophic Lateral Sclerosis , 2010, American Journal of Neuroradiology.

[21]  F Träber,et al.  Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. , 1998, Archives of neurology.

[22]  N Filippini,et al.  Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis , 2010, Neurology.

[23]  Peter B Barker,et al.  Spatial effects in the detection of γ‐aminobutyric acid: Improved sensitivity at high fields using inner volume saturation , 2007, Magnetic resonance in medicine.

[24]  A. Eisen,et al.  Duration of amyotrophic lateral sclerosis is age dependent , 1993, Muscle & nerve.

[25]  A Al-Chalabi,et al.  Abnormal cortical excitability in sporadic but not homozygous D90A SOD1 ALS , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[26]  A. Doble The pharmacology and mechanism of action of riluzole , 1996, Neurology.

[27]  M. Turner,et al.  Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? , 2012, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[28]  M. Garwood,et al.  Simultaneous in vivo spectral editing and water suppression , 1998, NMR in biomedicine.

[29]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[30]  T L Chenevert,et al.  Decreased motor cortex γ-aminobutyric acid in amyotrophic lateral sclerosis , 2012, Neurology.

[31]  Steven Knight,et al.  Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. , 2011, Brain : a journal of neurology.

[32]  D. Arnold,et al.  Recovery of N‐acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy , 1998, Neuroreport.

[33]  Jing Han,et al.  Study of the features of proton MR spectroscopy (1H‐MRS) on amyotrophic lateral sclerosis , 2010, Journal of magnetic resonance imaging : JMRI.

[34]  M. Kiernan,et al.  Riluzole, neuroprotection and amyotrophic lateral sclerosis. , 2010, Current medicinal chemistry.

[35]  P M Pattany,et al.  MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. , 2000, AJNR. American journal of neuroradiology.

[36]  C. Zorumski,et al.  Neuroprotective agent riluzole potentiates postsynaptic GABAA receptor function , 2002, Neuropharmacology.

[37]  M. Lauritzen,et al.  Reduced GABAergic inhibition explains cortical hyperexcitability in the wobbler mouse model of ALS. , 2011, Cerebral cortex.

[38]  P. Pattany,et al.  1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis , 1999, Journal of the Neurological Sciences.

[39]  S. Provencher Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[40]  K. Uğurbil,et al.  In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: Metabolite quantification at 4T vs. 7T , 2009, Magnetic resonance in medicine.

[41]  S. Petri,et al.  Distribution of GABAA Receptor mRNA in the Motor Cortex of ALS Patients , 2003, Journal of neuropathology and experimental neurology.

[42]  A. Ludolph,et al.  Protective Effects of Riluzole on Dopamine Neurons , 2000, Journal of neurochemistry.

[43]  P. Sundgren,et al.  Magnetic resonance spectroscopy. , 2005, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[44]  F. Turkheimer,et al.  Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study , 2004, Neurobiology of Disease.

[45]  M. Swash Why are upper motor neuron signs difficult to elicit in amyotrophic lateral sclerosis? , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[46]  T. Ng,et al.  1H-MRS evidence of neurodegeneration and excess glutamate glutamine in ALS medulla , 1999, Neurology.

[47]  M. Gobbi,et al.  Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. , 2008, European journal of pharmacology.

[48]  Robert G. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2012, The Cochrane database of systematic reviews.

[49]  J. Mantz,et al.  Riluzole, a novel antiglutamate, blocks GABA uptake by striatal synaptosomes. , 1994, European journal of pharmacology.

[50]  R. Edden,et al.  In vivo magnetic resonance spectroscopy of GABA: a methodological review. , 2012, Progress in nuclear magnetic resonance spectroscopy.